Teleflex (TFX) Receives FDA 510(k) Clearance to Market Arrow JACC w/ Chlorag+ard Technology

October 10, 2016 6:46 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Teleflex Incorporated (NYSE: TFX) has announced it has received FDA 510(k) clearance to market its Arrow JACC with Chlorag+ard Technology and TightTrack tunneler.

Arrow JACC with Chlorag+ard Technology is a long-term, tunneled, small french size antithrombogenic1 and antimicrobial2 central venous catheter designed to meet the needs of patients throughout their course of therapy or illness. The catheter is also designed for use with high-pressure injection for diagnostic studies. The Arrow JACC with Chlorag+ard Technology protects against catheter occlusion3, phlebitis4, and intimal hyperplasia4 for up to 30 days. The Arrow JACC with Chlorag+ard Technology will enable caregivers to effectively and economically preserve vessel access, and care for millions of end stage renal disease patients.

“At Teleflex, we are committed to providing the right line for the right patient at the right time™,” said Jay White, President of the Vascular Division. “We are proud to add the tunneled Arrow JACC to our line of vascular access products. By providing an antithromogenic1 and antimicrobial2 catheter that protects against catheter occlusion3, we are offering a technology that no one else can. This is especially important in patients with end stage renal disease where vessel health and preservation is essential to provide a future dialysis vascular access5.”

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA

Add Your Comment